Nitric oxide decreases the binding affinity of the AT1 receptor for angiotensin II via S-nitrosylation of cysteine 289, providing a molecular mechanism for NO's opposition to angiotensin II effects.
No takes yet. Share an insight, caveat, or question.
May inform NO-AT1 crosstalk in vascular disease; leaves open translation to human hypertension therapy.
Leclerc et al. (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: